Efficacy and Safety of PD-1 Inhibitors and Targeted Drugs Combined with Radiotherapy in First-Line Treatment of Oligometastatic Hepatocellular Carcinoma

被引：0
|
作者：
Zhu, K. [1 ]
Liu, J. [2 ]
Dou, X. [1 ]
Zhang, X. [1 ]
Xu, L. [1 ]
Shi, P. [2 ]
Shi, F. [1 ]
Yue, J. [1 ]
机构：
[1] Shandong First Med Univ & Shandong Acad Med Sci, Shandong Canc Hosp & Inst, Dept Radiat Oncol, Jinan, Peoples R China
[2] Shandong First Med Univ, Shandong Canc Hosp, Jinan, Shandong, Peoples R China
来源：
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS | 2024年 / 120卷 / 02期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
3126
引用
收藏
页码：E509 / E509
页数：1
相关论文
共 50 条
  • [31] The Safety of First-line and Subsequent Monotherapy of PD-1/PD-L1 Inhibitors in NSCLC: A Meta Analysis
    Yang, Y.
    Xie, Z.
    Pang, P.
    Wang, N.
    Liang, H.
    Zhao, L.
    JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (10) : S1048 - S1049
  • [32] Efficacy and safety of anlotinib as first-line treatment and followed by tyrosine kinase inhibitors (TKIs) combined with PD-1 blockades regimen after disease progression for advanced hepatocellular carcinoma (HCC): A real-world exploratory study.
    Li, Qing-Qing
    Ma, Sheng-Li
    Zhang, Lu
    Zhang, Xian-Qiang
    Gao, Xiao-Juan
    Pan, Yan-Feng
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16) : E16146 - E16146
  • [33] Efficacy and safety of anlotinib with PD-1 inhibitors in the treatment of advanced hepatocellular carcinoma: A real-world study.
    Chen, Kehe
    Huang, Xianshi
    Yu, Lei
    Lu, Jianxun
    Huang, Fei
    Wang, Zhiguang
    Wei, Yan
    Hou, Encun
    Luo, Min
    Huang, Shiqing
    Hu, Hongbo
    Ou, Mei
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 : 583 - 583
  • [34] Clinical Efficacy of PD-1 Inhibitors Plus Split-Course Radiotherapy in the First-Line Treatment of Advanced Kidney Cancer: A Randomized Controlled Trial
    Li, Weiping
    Cao, Zhigang
    Chang, Pengcheng
    Zhang, Bin
    Li, Fudong
    Chang, Dehui
    JOURNAL OF ONCOLOGY, 2022, 2022
  • [35] Efficacy and safety of switching other tyrosine kinase inhibitors to regorafenib combined with primary PD-1 antibodies in patients with hepatocellular carcinoma
    Pan, Shida
    Yu, Yingying
    Wang, Siyu
    Qiu, Qin
    Shen, Yingjuan
    Yang, Luo
    Liu, Xiaomeng
    Luan, Junqing
    Meng, Fanping
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [36] Efficacy and safety of hepatic arterial infusion chemotherapy combined with lenvatinib and PD-1 inhibitors for advanced hepatocellular carcinoma with macrovascular invasion
    Zhang, Yufeng
    Zhang, Haiyan
    Xu, Haoqian
    Wang, Ying
    Feng, Long
    Yi, Fengming
    WORLD JOURNAL OF SURGICAL ONCOLOGY, 2024, 22 (01)
  • [37] Efficacy, safety, and prognostic factors of PD-1 inhibitors combined with lenvatinib and Gemox chemotherapy as first-line treatment in advanced intrahepatic cholangiocarcinoma: a multicenter real-world study
    Zhu, Chengpei
    Li, Hu
    Yang, Xiaobo
    Wang, Shanshan
    Wang, Yunchao
    Zhang, Nan
    Wang, Yanyu
    Xue, Jingnan
    Zhang, Longhao
    Ning, Cong
    Yang, Xu
    Xun, Ziyu
    Chao, Jiashuo
    Long, Junyu
    Sang, Xinting
    Zhu, Zhenyu
    Zhao, Haitao
    CANCER IMMUNOLOGY IMMUNOTHERAPY, 2023, 72 (09) : 2949 - 2960
  • [38] Efficacy, safety, and prognostic factors of PD-1 inhibitors combined with lenvatinib and Gemox chemotherapy as first-line treatment in advanced intrahepatic cholangiocarcinoma: a multicenter real-world study
    Chengpei Zhu
    Hu Li
    Xiaobo Yang
    Shanshan Wang
    Yunchao Wang
    Nan Zhang
    Yanyu Wang
    Jingnan Xue
    Longhao Zhang
    Cong Ning
    Xu Yang
    Ziyu Xun
    Jiashuo Chao
    Junyu Long
    Xinting Sang
    Zhenyu Zhu
    Haitao Zhao
    Cancer Immunology, Immunotherapy, 2023, 72 : 2949 - 2960
  • [39] Efficacy and safety of PD-1/L1 inhibitors as first-line therapy for metastatic colorectal cancer: a meta-analysis
    Huang, Zhilong
    Li, Chunyan
    Huang, Yanping
    Liang, Weiming
    Tao, Haiyun
    FRONTIERS IN IMMUNOLOGY, 2024, 15
  • [40] Efficacy and Safety of TACE Combined with Regorafenib Plus PD-1 Inhibitor in the Treatment of Hepatocellular Carcinoma After Sorafenib Resistance
    Zou, Xinhua
    Xu, Qingyu
    You, Ran
    Yin, Guowen
    JOURNAL OF HEPATOCELLULAR CARCINOMA, 2023, 10 : 267 - 279
12345